期刊文献+

黄酮类化合物逆转肿瘤多药耐药作用的研究进展 被引量:3

Research progress on reversal of multidrug resistance in tumors by flavonoids
原文传递
导出
摘要 肿瘤多药耐药是肿瘤治疗过程中一个亟待解决的难题,其表现为肿瘤细胞对单一或多种化疗药物同时出现耐药性,从而导致治疗失败,与药物的化学结构和作用机制无关。将化疗药物与肿瘤多药耐药逆转剂联合应用是目前公认的治疗方案之一。黄酮类化合物由于其低毒、高效,具有多种药理作用等优点而受到广泛的关注。在肿瘤治疗期间,黄酮类化合物能通过抑制ABC转运体、诱导凋亡、调节氧化应激等作用逆转肿瘤多药耐药。归纳总结了黄酮类化合物逆转肿瘤多药耐药的主要机制、应用及其纳米剂型改造的进展,为进一步的临床研究提供参考。 Trumor multidrug resistance(MDR) is a problem that needs to be solved in the course of tumor treatment. MDR is characterized by the simultaneous emergence of resistance to single or multiple chemotherapeutic drugs in tumor cells resulting in treatment failure, regardless of the chemical structure and mechanism of the drug. Combining chemotherapeutic agents with MDR reversal agents is currently recognized as one of the treatment options. Flavonoids have received extensive attention because of their low toxicity, high efficiency, and their many pharmacological effects. During the treatment of tumors, flavonoids can reverse MDR by inhibiting ABC transporter, inducing apoptosis and regulating oxidative stress. This article summarizes the main mechanisms of flavonoids on reversal MDR and the progress of the modification of nano-formulations, in order to provide reference for further clinical research.
作者 金焕 谭爱萍 刘克辛 JIN Huan;TAN Aiping;LIU Kexin(Department of Pharmacy,the First Affiliated Hospital of Dalian Medical University,Dalian 116044,China;Department of Clinical Pharmacology,College of Pharmacy,Dalian Medical University,Dalian 116044,China)
出处 《药物评价研究》 CAS 2018年第6期945-951,共7页 Drug Evaluation Research
基金 国家自然科学基金资助项目(81473280) 辽宁省自然科学基金资助项目(20170540293)
关键词 肿瘤治疗 多药耐药 黄酮类化合物 药物转运体 cancer treatment multidrug resistance flavonoids drug transporter
  • 相关文献

参考文献5

二级参考文献42

  • 1肖希斌,谢兆霞,秦群.甲基莲心碱抑制K562/A02细胞GST-π的表达[J].西安交通大学学报(医学版),2005,26(5):428-430. 被引量:14
  • 2肖希斌,谢兆霞,陈杰,秦群,祝焱.甲基莲心碱在K562/A02细胞对STI571敏感性中的作用[J].中南大学学报(医学版),2005,30(5):558-561. 被引量:6
  • 3Petraccia L, Onori P’Sferra R,et al. MDH (Multidrug Resistance) inhepatocarcinoma clinical - therapeutic implications [J].Clin Ter ,2003, 154(5):325-335.
  • 4Westerlund M, Belin AC, Olson L, et al. Expression of multi-drugresistance 1 mRNA in human and rodent tissues: reduced levels inParkinson patients[J].Cell Tissue Res, 2008,334(2): 179-185.
  • 5Yoshioka S,Katayama K. The identification of two germ -linemutations in the human breast cancer resistance protein gene thatresult in the expression of a low/non-functional protein[J].J PharmRes, 2007,24(6):1108-1117.
  • 6Chikamori K,Hill JE, Grabowski DR, et al. Down regulation oftopoisomerase II beta in myeloid leukemia cell lines leads toactivation of apoptosis following all -trans retinoic acid -induceddifferentiation growth arrest [J].Leukemia, 2006,20 (10) : 1809-1818.
  • 7Linenberger ML,Hong T,Flowers D,et al.Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.Blood,2001;98(4):988-994.
  • 8Norgaard JM,Bukh A,Langkjer ST,et al.MDR1 gene expression and drug resistance of AML cells.Br J Haematol,1998;100(3):534-540.
  • 9Sun J,Yeung CA,Co NN,et al.Clitocine Reversal of P-Glycoprotein Associated Multi-Drug Resistance through Down-Regulation of Transcription Factor NF-κB in R-Hep G2 Cell Line.Plo S One,2012;7(8):e40720.
  • 10hauncey TR,Rankin C,Anderson JE,et al.A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia(AML)using mitoxantrone,etoposide and the MDR modulator PSC 833:a southwest oncology group study 9617.Leuk Res,2000;24(7):567-574.

共引文献930

同被引文献20

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部